Lexicon Pharma (LXRX) Reports In-Line Q1 Loss of 4c/Share
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.34 +0.86%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $1.1 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- RBC Capital Downgrades Hermes International (RMS:FP) (HESAY) to Sector Perform
- XP Inc eyes US banking license as next business step
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
